Recently, we could show that expression of constitutively active farnesylated Akt1 (CA-Akt) renders MCF10A mammary epithelial cells and A549 non-small-cell lung cancer (NSCLC) cells more resistant to the treatment with cell cycle independent chemotherapeutics such as cisplatin and Mitoxantrone (Schmidt et al, 2002). This evidence concerns the gene AKT1 and non-small cell lung carcinoma.